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Purpose: To report the dosimetric results and impact of volumetric arc therapy (VMAT) on temporary alopecia and
hair-loss related quality of life (QOL) in whole brain radiotherapy (WBRT).
Methods: The potential of VMAT-WBRT to reduce the dose to the hair follicles was assessed. A human cadaver was
treated with both VMAT-WBRT and conventional opposed field (OF) WBRT, while the subcutaneously absorbed dose
was measured by radiochromic films and calculated by the planning system. The impact of these dose reductions
on temporary alopecia was examined in a prospective phase II trial, with the mean score of hair loss at 1 month
after VMAT-WBRT (EORTC-QOL BN20) as a primary endpoint and delivering a dose of 20 Gy in 5 fractions. An interim
analysis was planned after including 10 patients to rule out futility, defined as a mean score of hair loss exceeding
56.7. A secondary endpoint was the global alopecia areata severity score measured with the “Severity of Alopecia
Tool” (SALT) with a scale of 0 (no hair loss) to 100 (complete alopecia).
Results: For VMAT-WBRT, the cadaver measurements demonstrated a dose reduction to the hair follicle volume
of 20.5% on average and of 41.8% on the frontal-vertex-occipital medial axis as compared to OF-WBRT. In the
phase II trial, a total of 10 patients were included before the trial was halted due to futility. The EORTC BN20
hair loss score following WBRT was 95 (SD 12.6). The average median dose to the hair follicle volume was
12.6 Gy (SD 0.9), corresponding to a 37% dose reduction compared to the prescribed dose. This resulted in a mean
SALT-score of 75.
Conclusions: Compared to OF-WBRT, VMAT-WBRT substantially reduces hair follicle dose. These dose reductions could
not be related to an improved QOL or SALT score.Introduction
Whole brain radiotherapy (WBRT) increases survival in
patients with brain metastases [1-3], but has also been
shown to reduce Quality of Life (QOL) by increasing
drowsiness, leg weakness and hair loss [4]. Hair loss is
typically observed in all patients undergoing WBRT [5]
and was reported as one of the main factors reducing* Correspondence: piet.ost@ugent.be
1Department of Radiotherapy and Experimental Cancer Research, Ghent
University, De Pintelaan 185, Ghent, Belgium
3Department of Radiotherapy, Ghent University Hospital, De Pintelaan 185,
Ghent, Belgium
Full list of author information is available at the end of the article
© 2014 De Puysseleyr et al.; licensee BioMed C
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.QOL scores when WBRT is used in the prophylactic
setting in small cell lung cancer [6].
The standard WBRT technique applies 2 lateral op-
posed fields (OF-WBRT) with a margin around the
brain including the hair follicles, which are located
approximately 5 mm below the scalp [7]. Irradiation-
induced epilation is due to high susceptibility of anagen
follicles to radiation [8]. Complete hair regrowth gener-
ally occurs 2–4 months after irradiation [8], which
often exceeds the life expectancy in poor prognostic
patients. Therefore, significant gains in QOL might be
obtained by developing a hair sparing WBRT technique.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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and radiotherapy treatment planning may allow us to treat
the whole brain with reduced margins, allowing better
sparing of the scalp [9-11]. Furthermore, the use of arc
techniques may minimize the follicle dose, as the reduc-
tion of surface dose is then distributed over the length of
the arc [12].
The purpose of this study was to investigate the im-
pact of VMAT-WBRT on temporary alopecia and hair
loss related QOL. The dose-effect relation of temporary
alopecia is, however, poorly investigated and, to our
knowledge, the available data remain limited to perman-
ent alopecia [12,13]. Furthermore, plan optimization and
evaluation for the hair follicle volume is impeded by the
known inaccuracies of the treatment planning system in
calculating build-up doses [14]. In order to overcome
these issues, our study combines a dosimetric study and
a prospective phase II trial for the treatment of patients
with brain metastases, relating the measured and com-




In order to quantify the potential of VMAT-WBRT to
reduce the dose to the hair follicles and to evaluate the
treatment planning system’s accuracy in predicting these
values, a human Thiel-embalmed cadaver [15] implanted
with 13 radiochromic films in the scalp was treated with
both OF- and VMAT-WBRT (Ghent University Hospital
Institutional Review Board reference EC UZG 2012/401).
Treatment techniques
The OF-WBRT plan consisted of two lateral opposed
beams, with the gantry at 90 and 270 degrees with the
field borders set at 2 cm beyond the bony skeleton in
the superior, anterior and posterior direction. The colli-
mator was rotated to allow the inferior border to parallel
the base of skull. The inferior border was set from theFigure 1 The hair follicle volume was defined as the tissue underlying
was written in Pinnacle, version 9.0 (Philips Medical Systems, Andover, MA,
subvolumes representing the different areas of the scalp: top (vertex, pink),
scalp, blue) and right (right profile of the scalp, red). Panel A: frontal view,bony canthus to the C1-2 interverebral space, covering
the base of skull with a 1-cm margin. The VMAT-
WBRT plan used a single arc of 352° (from −176° to
+176°) without gaps in delivery. Both techniques
employed 6 MV photons from a linear accelerator
equipped with an MLCi2 multileaf collimator (Elekta
Synergy, Elekta, Crawley, UK). The clinical target vol-
ume was the whole brain (to the inner table of the skull
and 1 cm inferior for the foramen magnum), delineated
on a contrast edical Systems, Tokyo, Japan) and expanded
with 2 mm in all directions creating a planning target
volume (PTV) for both techniques. The hair follicle vol-
ume was defined as the tissue underlying the skin up to
the outer table of the skull. An automated script was
written in Pinnacle, version 9.0 (Philips Medical Sys-
tems, Andover, MA, US), to automatically contour this
volume with the creation of 4 subvolumes representing
the different areas of the scalp (Figure 1): top (vertex),
back (posterior aspect of the scalp), left (left profile of the
scalp) and right (right profile of the scalp) [16]. A median
dose of 20 Gy (5 fractions) was prescribed to the PTV
according the ICRU recommendations (95% - 107%)
[17] while the dose to the hair follicle volume was re-
duced maximally without compromising the dose to the
brain. Optimization and dose calculation were first
performed using the VMAT-extended GRaTiS pro-
gram [18,19] with final dose calculations in Pinnacle.
During treatment, the cadaver was positioned on a
personalized head support and immobilized with a
thermoplastic mask (Marcomedics, Waddinxveen, The
Netherlands). The positioning of the brain was cor-
rected using cone beam CT, with co-registration based
on the bony anatomy [20].
Radiochromic film dosimetry
Thirteen radiochromic films (2.2 × 2.2 cm2, EBT2 lot nr.
A06271203, Gafchromic, Ashland Specialty Ingredients,
Wayne, NJ, USA) were implanted equally distributed
across the cadaver scalp (Figure 2). They were protectedthe skin up to the outer table of the skull. An automated script
US), to automatically contour this volume with the creation of 4
back (posterior aspect of the scalp, orange), left (left profile of the
panel B, lateral view, panel C: cranial view.
Figure 2 Distribution of the film measurement locations across the scalp.
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them in a plastic paraffin film casing (Parafilm, Pechi-
ney Plastic Packaging Company, Chicago, Illinois). As
the internal structure of the cadaver skin cannot be
discerned macroscopically, all films were implanted
subcutaneously. Consequently, their implantation depth
always exceeded the hair follicle depth. Moreover, all films
were positioned within the build-up region with doses
generally rising with depth. Therefore, we assume their
measured doses to serve as an estimation and upper limit
for the dose to the hair follicles. The implantation
depth was estimated using CT images and ranged from
2.0 to 11.7 mm.
Radiochromic films were digitized on an Epson Ex-
pression 10000XL flatbed scanner (Seiko Epson Corpor-
ation, Suwa, Nagano, Japan) and analyzed using the net
optical density (OD) in the red color channel [21]. The
mean doses and dose-volume-histograms were com-
puted for the complete films, only excluding a narrow
strip along the film’s edge and the small orientation
markers on the film. All reported relative doses and
dose differences are normalized to both plans’ prescrip-
tion dose (per fraction) of 4 Gy.
The films were not present in the cadaver during
planning CT imaging. Instead, the visibility of their
positions was enhanced by replacing them with 2.2 ×
2.2 × 0.02 cm3 aluminum plates. We observed no im-
paired image distortion for the applied CT settings. The
films were exposed to the kV-irradiation of the CBCT
cadaver during positioning procedures. The impact of
these procedures on the films’ OD was assessed by
exposing one set of films to the CBCT irradiation only.
As the CBCT induced film response corresponded to
only 0.56% of the prescription dose on average, the
CBCT-related film darkening was neglected in further
experiments.
Dose calculation accuracy
The dose calculation accuracy of the collapsed-cone
convolution (CCC) algorithm implemented in Pinnaclewas evaluated by comparing the measured and calcu-
lated data. To that purpose, the outline of the aluminum
plates in the CT images served for contouring the loca-
tion of the radiochromic films. The density within these
contours was overridden with the density of the sur-
rounding dermal tissue (1.07 g/cm3). As the calculation
grid is generally considered a determinative parameter
for dose calculation accuracy in the build-up region [14],
the calculations were performed for both the clinically
used 4 mm, as well as for a 1 mm calculation grid.
Within these computations, the fluence density grid
always equaled the calculation grid. The mean absorbed
doses and dose-volume-histograms were then computed
for all radiochromic film positions.
Phase II study
Patients and procedures
Eligible patients who presented at the department of
radiation oncology of Ghent University Hospital were
recruited for the study. Eligibility requirements were:
age ≥18, brain metastases eligible for WBRT: recursive
partitioning analysis (RPA) class I or II and > 3 brain
metastases or RPA class III or meningitis carcinoma-
tosa, and signed written informed consent. Patients
were excluded if they received prior cranial radiother-
apy, had pre-existing alopecia or were diagnosed with
leukemia, lymphoma or germ-cell tumor. The study
was approved by the local Institutional Review Board
(reference number: EC2011/504) and registered at clin-
icaltrials.gov: NCT01421316.
All patients received VMAT-WBRT for brain metasta-
ses detected with brain contrast-enhanced computed
tomography and/or magnetic resonance imaging within
1 month before enrolment. The delineation, treatment
planning and delivery for the VMAT technique has been
described above. The primary endpoint was the mean
score of hair loss at 1 month after VMAT-WBRT scored
with the European Organization for Research and Treat-
ment of Cancer (EORTC) Quality of Life Questionnaire
Brain Cancer Module (EORTC-QLQ-BN20) [22]. The
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undergoing chemotherapy or radiotherapy, and is com-
posed of 20 questions assessing visual disorders, motor
dysfunction, communication deficit, various disease
symptoms (e.g., headaches and seizures), treatment
toxicities (e.g., hair loss), and future uncertainty. This
questionnaire was used as a supplement to the EORTC-
QLQ-C15-PAL [23]. The questions on both measures
were scaled, scored and reported using the recommended
EORTC procedures [24,25]. As a secondary endpoint, the
global alopecia areata severity score was used (combin-
ation of extent and density of scalp hair loss) [16]. The
total score is calculated by visually determining the
amount of terminal hair loss in each of the four views of
the scalp and adding these together with a maximum
score of 100% corresponding with complete alopecia.
This global severity score may be called the “Severity of
Alopecia Tool” or SALT score. The four views of the
scalp were photographed in standardized conditions be-
fore radiotherapy and 1 month after radiotherapy [16].
Sample size and statistical analysis
At 1 month following OF-WBRT, the mean score of hair
loss (EORTC BN20) is 36.7 (out of 100, with a standard
deviation of 17) compared to 11.7 in an untreated pa-
tient group [6]. We hypothesize that with VMAT-WBRT,
the mean score of hair loss will be 15 points lower com-
pared to OF-WBRT [25]. Differences of at least 10 points
(on a 0 to 100 scale) are classified as the minimum clinic-
ally meaningful change in the mean value of a HRQOL
parameter. Mean changes of more than 20 points were
classed as large effects. To detect a significant result at the
5% level, with 80% power we would need to treat 21 pa-
tients in this single arm study. With an estimated dropout
of 20%, due to the median prognosis of 2 months, weFigure 3 DVH’s for the VMAT- and OF- WBRT cadaver plans calculatedaimed to include 26 patients. Descriptive statistics were
used to calculate means and standard deviations. The
QOL and SALT score results are presented as mean
scores and were compared between time points using
the Wilcoxon signed rank test (p < 0.05 considered
significant). An interim analysis was planned after
including 10 patients to rule out futility, defined as a
mean score of hair loss exceeding 56.7.
Results
Dosimetric evaluation
The cadaver’s planning results are depicted in Figure 3,
demonstrating the DVH’s calculated with a 1 mm dose
grid, and Table 1, showing the corresponding calculated
median doses. Compared to the OF-plan, the VMAT
computations clearly predict a mean dose decrease of
approximately 25% in the total hair follicle volume. The
highest reductions are found in the hair top and back
subvolumes, where a high-dose region in the OF-plan is
transformed into a low dose region for the VMAT-plan.
As illustrated in Table 2, our radiochromic film
measurements conclusively confirmed these predicted
tendencies. For all films in the VMAT-plan, an important
dose reduction was found compared to the OF-plan, with
an average film dose reduction of 20.5%. As predicted
by the TPS, the OF-plan demonstrated a remarkable
high-dose region on the hair top and back subvolumes
(mean dose 112.2% for films 8, 11–13), which is trans-
formed into a low dose region in the VMAT-plan (mean
dose 70.4%).
The calculation accuracy of the mean dose of the film
was found to be similar for both techniques, except for
the films on the frontal-vertex-occipital medial axis. For
the clinically used 4 mm calculation grid, the mean dose
discrepancy between measurements and calculationswith a 1 mm dose grid for 1 fraction (prescription dose 4 Gy).
Table 1 Calculated median doses (D50) for the hair follicle volume and its subvolumes for the VMAT- and OF- plan




Calculated D50 Calculated D50 Calculated D50 Calculated D50
1 mm grid (%) 4 mm grid (%) 1 mm grid (%) 4 mm grid (%)
Total 72.4 68.5 100.10 92.34
Top 67.3 60.8 106.60 90.79
Left 81.4 78.4 97.58 92.92
Back 62.3 59.8 103.40 94.09
Right 80 75.9 93.99 89.82
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spectively. In the OF-plan, however, the use of this
4 mm grid resulted in remarkable accuracy degradation
on the frontal-vertex-occipital medial axis. The high
dose in this region was then underestimated by 16.22%
on average and 22.9% at maximum. In the correspond-
ing lower dose region in the VMAT-plan, this tendency
was much less pronounced, demonstrating a mean dose
discrepancy of 8.2% only. The use of a 1 mm calculation
grid size resolved this issue. The average dose discrep-
ancy then amounted to 4.3% and 4.1% for the VMAT-
and OF- plan respectively with a maximum discrepancy
of 3.2% on the frontal-vertex-occipital medial axis.Table 2 mean measured and calculated doses for all films imp













1 2.53 91.0 89.0
2 5.74 85.6 85.0
3 9.74 85.9 89.6
4 6.34 77.9 78.0
Mean 6.09 85.1 85.4
Right
5 11.65 94.5 85.0
6 6.73 96.5 91.0
7 8.8 90.2 81.7
Mean 9.06 93.7 85.9
Back
8 7.24 71.2 69.7
9 2.53 83.9 79.8
10 11.04 81.0 85.7
Mean 6.94 78.7 78.4
Top
11 4.68 75.2 70.4
12 2.02 84.3 81.1
13 2.03 51.1 59.7
Mean 2.91 70.2 70.4
All films Mean 6.24 82.2 80.4
The corresponding standard deviations, representing dose variations within each fil
respectively. As the dose-volume-histograms for all detectors equally showed little
the mean dose per film.Phase II trial
A total of 10 patients were included between 26/10/11
and 25/05/2012 before the trial was halted due to futility
at time of the interim analysis. We treated 6 male and 4
female patients; with a median age of 63 years (range
45–72). The primary tumour site was lung (n = 5), pan-
creas (n = 2), breast, prostate and colon. All patients
were RPA class I (n = 5) or II (n = 5). The median num-
ber of metastases treated was 4 (range: 1–7).
As illustrated in Table 3, the average median dose to
the hair follicle volume was 12.6 Gy (SD 0.9), which
corresponds to a 37% dose reduction compared to the









1 mm grid (%)
Calculated dose
4 mm grid (%)
85.3 103.8 94.1 91.1
82.1 101.1 98.5 94.2
88.3 94.1 98.3 95.0
77.2 98.0 105.9 97.0
83.2 99.2 99.2 94.3
82.9 97.9 103.9 96.7
89.0 94.9 99.8 95.8
81.1 98.5 102.9 97.0
84.4 97.1 102.2 96.5
69.1 110.4 109.9 103.3
78.6 100.0 101.7 96.8
85.1 98.5 102.7 97.8
77.6 102.9 104.8 99.3
64.2 114.2 111.8 91.5
70.4 112.3 111.4 89.4
56.9 111.9 108.9 99.7
63.9 112.8 110.7 93.5
77.7 102.7 103.8 95.8
m, amounted to approximately 3.5% and 1.9% for the VMAT- and OF- films
dose variation within each film, further data analysis was uniquely based on
Table 3 Patient planning results of the phase II trial for the different hair follicle subvolumes for 5 fractions










V5 ± SD (%)
Mean
V10 ± SD (%)
Mean
V15 ± SD (%)
Mean
V20 ± SD (%)
Total 75 ± 13 12.6 ± 0.9 62.9 92.2 ± 4.2 66.8 ± 6.4 31.1 ± 9.3 0.4 ± 0.8
Left 96 ± 0.05 15.7 ± 0.8 78.4 86.1 ± 1.5 79.8 ± 8.5 51.6 ± 8.5 0 ± 0
Right 96 ± 0.05 16.0 ± 0.9 80.0 85.6 ± 2.3 78.9 ± 4.5 50.5 ± 7.1 0 ± 0
Back 60 ± 18.7 10.5 ± 1.3 52.3 77.9 ± 6.8 45.0 ± 10.6 12.8 ± 9.2 0 ± 0
Top 65 ± 18.3 11.3 ± 2.7 56.3 76.6 ± 11.3 49.9 ± 18.4 21.8 ± 16.8 0.6 ± 2
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20%, 44% and 48% for the left side, right side, top of
head and back of head, respectively. For all hair follicle
subvolumes, the mean doses predicted by the TPS for the
patient group differed by only 7.3% at maximum from the
corresponding doses calculated for the cadaver.
Two patients died before reaching 1 month follow-up.
For the remaining 8 patients, the mean score of hair
loss, as measured with the EORTC BN20 questionnaire
prior to WBRT, was 9.5 (SD 16.2) compared to 95 (SD
12.6) after WBRT (p = 0.01). The mean total SALT score
before WBRT was 0 (SD 0) compared to 75 (SD 13)
after WBRT, corresponding to 75% hair loss. One patient
was excluded from the photographic scoring after shav-
ing his head. When sub-stratifying the score according
to the four subvolumes, we observed a mean hair loss of
96%, 96%, 65% and 60% at the left side, right side, top of
scalp and back of scalp, respectively (p = 0.04). A lateral
view of a patient with 55% hair loss according to the
SALT- score is depicted in Figure 4.
Discussion
In literature, the interpretation of data on intensity modu-
lated techniques in hair-sparing WBRT [10,11] has beenFigure 4 Lateral view of a patient’s scalp with a 55% hair loss accordingimpeded by the lack of knowledge on the dose-effect rela-
tion of temporary alopecia. Additionally, plan optimization
and evaluation in the hair follicle region is limited by
known inaccuracies of the TPS in calculating build-up
doses [14]. As a consequence, the available dosimetric
studies by Roberge et al. [11] and Mancini et al. [10] do
not allow to predict these techniques’ impact on tempor-
ary alopecia. This investigation is, to our knowledge, the
first study to overcome these issues by quantitatively relat-
ing dose measurements and planning data to clinical re-
sults on temporary alopecia in WBRT.
In this respect, our dose measurements demonstrated
the potential of VMAT-WBRT to reduce the subcutane-
ously absorbed dose by 20.5%. Roberge et al., for com-
parison, measured a dose reduction of 53% at 1 mm
depth with TLD’s and calculated a dose reduction of
38% within the first 5 mm of the skin when comparing
IMRT to OF-WBRT [11]. Note, however, that our study
reports the subcutaneously absorbed dose, serving as an
upper limit for hair follicle dose, rather than the dose
measured at the surface by Roberge et al.. Conse-
quently, as the sparing of any organ at risk depends on
its distance to the target volume, the sparing of the
more superficially positioned hair follicles will mostto the SALT-score, but scoring 100 on the EORTC hair loss scale.
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values [11]. Interestingly, the lowest doses in VMAT-
WBRT were found on the top of the scalp, where high
doses typically occur in OF-WBRT. These high OF-
doses might be attributed to the extremely oblique and
overlapping incidence of opposed beams, thus boosting
surface dose and degrading the modeling accuracy of
the TPS. The use of arc techniques obviously mitigates
this effect by spreading it out across the scalp. Com-
bined with the concomitant lack of exit dose in this
region compared to the remainder of the scalp, this
effect results in a low dose region in the VMAT-plan. A
more optimized OF-WBRT could probably improve the
doses to the hair follicle region, when using portals
shaped around the PTV, the use of compensation and
higher energy photons.
Most importantly, our phase II trial provided valuable
insight into the impact of these dose reductions on the
risk of temporary alopecia. As for the human cadaver,
the patients’ doses in the hair follicle left and hair right
subvolumes were predicted to be around 15–17 Gy for 5
fractions respectively and were related to 96% hair loss.
However, as for the cadaver, the TPS equally predicted
a low dose region of 10.5-11.3 Gy on the frontal-vertex-
occipital medial axis (top and back subvolumes), result-
ing in 60 to 65% hair loss. Based on these data, we
hypothesize that the threshold TPS dose for temporary
alopecia is around or slightly lower than 10 Gy in 5
fractions, as some but not all of the patients retained
their hair in this region. In contrast, in the abstract of
Ting et al. a mean calculated scalp dose of 18.5 Gy
(within the first 3 mm of tissue underlying the skin)
delivered in 10–15 fractions in IMRT-WBRT was re-
lated to subjectively reduced hair loss in all patients.
Half of the patients demonstrated no noticeable hair
loss, while the other half experienced subjectively mild
hair loss. However, they neither quantitatively scored
hair-loss nor assessed QOL, making it difficult to com-
pare results.
Although some patients retained their hair on the top
and back of the head, this was not related to an im-
proved QOL. Following a pre-planned interim analysis,
the rules for futility were met, with a mean score of hair
loss exceeding 56.7 on the EORTC BN20 (mean score of
95). The score of hair loss in our study was higher than in
the literature, where in general scores between 30 and 40
are reported [4,6,26,27]. In the study of Steinman et al.
and Slotman et al., 42% and 22% of patients showed an
increase in hair loss scores exceeding 20 points, respect-
ively, compared to all patients in our study. In a recent
study of VMAT-WBRT with simultaneous integrated
boost for brain metastases, the mean score of hair loss
was 23.8 [28], which is lower compared to literature of
OF-WBRT and in range of our primary objective tolower the score to 21.7. We hypothesize that the worse
score in the current study compared to literature is due
to the patients’ knowledge of the primary goal of
VMAT-WBRT to reduce hair loss. This discordance is
reflected in Figure 4, showing a lateral view of a patient
scoring 100 on the EORTC hair loss scale although hair
loss was only 55% according to the SALT score.
Further improvements to reduce alopecia might re-
quire the combination of a reduced dose to the hair
follicles in combination with radioprotectors designed
to reduce the damage to the normal tissues caused by
radiation, such as nitroxides, antioxidants [29]. As an
alternative, the dose to the uninvolved brain might be
decreased to reduce toxicity. This approach is currently
tested with hippocampal sparing to avoid memory loss
[30]. However, a dose reduction to the peripheral zone
of the brain to avoid alopecia should be approached
carefully as most brain metastases are located in the
outer cortex of the brain [30].
Conclusion
Compared to OF-WBRT, VMAT-WBRT substantially
reduces hair follicle dose, especially on the frontal-
vertex-occipital medial axis. Our phase II trial was
halted due to futility with a EORTC BN20 hair loss
score of 95 (SD 12.6) and a mean SALT score of 75.
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